Trial Profile

Phase 2b study of ARQ151 in the patients with atopic dermatitis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Roflumilast (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use

Most Recent Events

08 Sep 2020 According to an Arcutis Biotherapeutics media release, company is planning phase 3 trial, following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), without conducting the previously planned Phase 2b atopic dermatitis trial.
17 Jan 2020 New trial record
16 Jan 2020 According to an Arcutis media release, this trial is expected to begin in the second half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com